Published in Nucleic Acids Res on December 25, 1990
Cyclic AMP in prokaryotes. Microbiol Rev (1992) 5.44
Promoters responsive to DNA bending: a common theme in prokaryotic gene expression. Microbiol Rev (1994) 3.81
Protein-protein communication within the transcription apparatus. J Bacteriol (1993) 3.75
Transcription activation at class II CAP-dependent promoters: two interactions between CAP and RNA polymerase. Cell (1996) 2.88
Escherichia coli catabolite gene activator protein mutants defective in positive control of lac operon transcription. J Bacteriol (1991) 2.18
Functional map of the alpha subunit of Escherichia coli RNA polymerase: two modes of transcription activation by positive factors. Proc Natl Acad Sci U S A (1991) 2.14
Identification of the activating region of catabolite gene activator protein (CAP): isolation and characterization of mutants of CAP specifically defective in transcription activation. Proc Natl Acad Sci U S A (1993) 2.08
E. coli RNA polymerase, deleted in the C-terminal part of its alpha-subunit, interacts differently with the cAMP-CRP complex at the lacP1 and at the galP1 promoter. Nucleic Acids Res (1993) 1.88
The role of two surface exposed loops in transcription activation by the Escherichia coli CRP and FNR proteins. Nucleic Acids Res (1991) 1.83
Catabolite gene activator protein activation of lac transcription. J Bacteriol (1992) 1.78
The structure of a CAP-DNA complex having two cAMP molecules bound to each monomer. Proc Natl Acad Sci U S A (1997) 1.74
Transcription activation at Class II CRP-dependent promoters: identification of determinants in the C-terminal domain of the RNA polymerase alpha subunit. EMBO J (1998) 1.73
The functional subunit of a dimeric transcription activator protein depends on promoter architecture. EMBO J (1994) 1.70
Probing the structure, function, and interactions of the Escherichia coli H-NS and StpA proteins by using dominant negative derivatives. J Bacteriol (1996) 1.67
Both fis-dependent and factor-independent upstream activation of the rrnB P1 promoter are face of the helix dependent. Nucleic Acids Res (1992) 1.56
Positioning of two alpha subunit carboxy-terminal domains of RNA polymerase at promoters by two transcription factors. Proc Natl Acad Sci U S A (1997) 1.56
Synergistic activation of transcription by Escherichia coli cAMP receptor protein. Proc Natl Acad Sci U S A (1993) 1.54
Antirepression function in Escherichia coli for the cAMP-cAMP receptor protein transcriptional activator. Proc Natl Acad Sci U S A (1992) 1.54
A simple mechanism for co-dependence on two activators at an Escherichia coli promoter. EMBO J (2001) 1.43
DNA binding and bending are necessary but not sufficient for Fis-dependent activation of rrnB P1. J Bacteriol (1993) 1.43
Unusually Situated Binding Sites for Bacterial Transcription Factors Can Have Hidden Functionality. PLoS One (2016) 1.39
Transcription activation at class II CRP-dependent promoters: the role of different activating regions. Nucleic Acids Res (1997) 1.34
Determinants of the C-terminal domain of the Escherichia coli RNA polymerase alpha subunit important for transcription at class I cyclic AMP receptor protein-dependent promoters. J Bacteriol (2002) 1.33
Dual-function regulators: the cAMP receptor protein and the CytR regulator can act either to repress or to activate transcription depending on the context. Proc Natl Acad Sci U S A (1996) 1.31
Transcription activation at the Escherichia coli uhpT promoter by the catabolite gene activator protein. J Bacteriol (1995) 1.27
The cyclic AMP receptor protein is the main activator of pectinolysis genes in Erwinia chrysanthemi. J Bacteriol (1997) 1.26
Orientation of functional activating regions in the Escherichia coli CRP protein during transcription activation at class II promoters. Nucleic Acids Res (1996) 1.25
Activation defects caused by mutations in Escherichia coli rpoA are promoter specific. J Bacteriol (1992) 1.24
Type 1 fimbriae, a colonization factor of uropathogenic Escherichia coli, are controlled by the metabolic sensor CRP-cAMP. PLoS Pathog (2009) 1.20
Mycobacterium tuberculosis cAMP receptor protein (Rv3676) differs from the Escherichia coli paradigm in its cAMP binding and DNA binding properties and transcription activation properties. J Biol Chem (2009) 1.15
ToxR proteins with substitutions in residues conserved with OmpR fail to activate transcription from the cholera toxin promoter. J Bacteriol (1992) 1.13
CRP induces the repositioning of MalT at the Escherichia coli malKp promoter primarily through DNA bending. EMBO J (1994) 1.13
Construction and characterization of a mercury-independent MerR activator (MerRAC): transcriptional activation in the absence of Hg(II) is accompanied by DNA distortion. EMBO J (1993) 1.08
ToxR interferes with CRP-dependent transcriptional activation of ompT in Vibrio cholerae. Mol Microbiol (2002) 1.07
Transcription activation at Escherichia coli promoters dependent on the cyclic AMP receptor protein: effects of binding sequences for the RNA polymerase alpha-subunit. Biochem J (1995) 1.06
Catabolite gene activator protein mutations affecting activity of the araBAD promoter. J Bacteriol (1998) 1.06
Structure of open promoter complexes with Escherichia coli RNA polymerase as revealed by the DNase I footprinting technique: compilation analysis. Nucleic Acids Res (1995) 1.05
Phage phi 29 regulatory protein p4 stabilizes the binding of the RNA polymerase to the late promoter in a process involving direct protein-protein contacts. Proc Natl Acad Sci U S A (1992) 1.05
Transcription activation by Escherichia coli FNR protein: similarities to, and differences from, the CRP paradigm. Nucleic Acids Res (1998) 1.05
The Escherichia coli RNA polymerase alpha subunit linker: length requirements for transcription activation at CRP-dependent promoters. EMBO J (2000) 1.04
Influence of DNA geometry on transcriptional activation in Escherichia coli. EMBO J (1996) 1.03
DNA deformation in nucleoprotein complexes between RNA polymerase, cAMP receptor protein and the lac UV5 promoter probed by singlet oxygen. EMBO J (1992) 1.02
Structural kinetics of transcription activation at the malT promoter of Escherichia coli by UV laser footprinting. Proc Natl Acad Sci U S A (1997) 1.02
Interactions between the Escherichia coli cAMP receptor protein and the C-terminal domain of the alpha subunit of RNA polymerase at class I promoters. Biochem J (1999) 1.00
Interplay between CRP-cAMP and PII-Ntr systems forms novel regulatory network between carbon metabolism and nitrogen assimilation in Escherichia coli. Nucleic Acids Res (2007) 1.00
DNA bending and expression of the divergent nagE-B operons. Nucleic Acids Res (1998) 0.99
Mutations in the tyrR gene of Escherichia coli which affect TyrR-mediated activation but not TyrR-mediated repression. J Bacteriol (1993) 0.99
Protein acetylation dynamics in response to carbon overflow in Escherichia coli. Mol Microbiol (2015) 0.99
An N-terminal mutation in the bacteriophage T4 motA gene yields a protein that binds DNA but is defective for activation of transcription. J Bacteriol (1996) 0.98
Mutations affecting two adjacent amino acid residues in the alpha subunit of RNA polymerase block transcriptional activation by the bacteriophage P2 Ogr protein. J Bacteriol (1994) 0.97
DNA bending by AraC: a negative mutant. J Bacteriol (1998) 0.95
DNA binding specificity and sequence of Xanthomonas campestris catabolite gene activator protein-like protein. J Bacteriol (1992) 0.94
Roles of catabolite activator protein sites centered at -81.5 and -41.5 in the activation of the Klebsiella aerogenes histidine utilization operon hutUH. J Bacteriol (1994) 0.94
Spacing requirements for interactions between the C-terminal domain of the alpha subunit of Escherichia coli RNA polymerase and the cAMP receptor protein. Biochem J (1998) 0.92
A common role of CRP in transcription activation: CRP acts transiently to stimulate events leading to open complex formation at a diverse set of promoters. EMBO J (1998) 0.92
CRP interacts with promoter-bound sigma54 RNA polymerase and blocks transcriptional activation of the dctA promoter. EMBO J (1998) 0.91
Downregulation of the Escherichia coli guaB promoter by upstream-bound cyclic AMP receptor protein. J Bacteriol (2009) 0.89
Mutational uncoupling of the transcriptional activation function of the TyrR protein of Escherichia coli K-12 from the repression function. J Bacteriol (1993) 0.89
Analysis of the spacer DNA between the cyclic AMP receptor protein binding site and the lac promoter. J Bacteriol (1996) 0.89
Repression of deoP2 in Escherichia coli by CytR: conversion of a transcription activator into a repressor. EMBO J (2001) 0.88
The cAMP receptor protein CRP can function as an osmoregulator of transcription in Escherichia coli. Genes Dev (1999) 0.87
Cyclic AMP receptor protein regulates pheromone-mediated bioluminescence at multiple levels in Vibrio fischeri ES114. J Bacteriol (2013) 0.87
A cyclic AMP receptor protein mutant that constitutively activates an Escherichia coli promoter disrupted by an IS5 insertion. J Bacteriol (1999) 0.86
Regulation of the Salmonella typhimurium pepT gene by cyclic AMP receptor protein (CRP) and FNR acting at a hybrid CRP-FNR site. J Bacteriol (1997) 0.85
Precise excision of IS5 from the intergenic region between the fucPIK and the fucAO operons and mutational control of fucPIK operon expression in Escherichia coli. J Bacteriol (2010) 0.84
Transcriptional regulation by BglJ-RcsB, a pleiotropic heteromeric activator in Escherichia coli. Nucleic Acids Res (2013) 0.83
Effects of crp deletion in Salmonella enterica serotype Gallinarum. Acta Vet Scand (2007) 0.82
The cyclic AMP receptor protein is dependent on GcvA for regulation of the gcv operon. J Bacteriol (1999) 0.82
The tib adherence locus of enterotoxigenic Escherichia coli is regulated by cyclic AMP receptor protein. J Bacteriol (2011) 0.82
Cyclic AMP receptor protein regulates cspD, a bacterial toxin gene, in Escherichia coli. J Bacteriol (2014) 0.80
Cyclic AMP receptor protein regulates cspE, an early cold-inducible gene, in Escherichia coli. J Bacteriol (2011) 0.80
Mutations in transcriptional regulators allow selective engineering of signal integration logic. MBio (2014) 0.78
Binding of the cyclic AMP receptor protein of Escherichia coli and DNA bending at the P4 promoter of pBR322. Biochem J (1992) 0.77
CRP-cyclic AMP dependent inhibition of the xylene-responsive σ(54)-promoter Pu in Escherichia coli. PLoS One (2014) 0.76
Cyclic AMP receptor protein: role in transcription activation. Science (1984) 8.37
Versatile low-copy-number plasmid vectors for cloning in Escherichia coli. Gene (1982) 6.62
Plasmid vector pBR322 and its special-purpose derivatives--a review. Gene (1986) 6.52
Plasmid vectors for the selection of promoters. Gene (1984) 6.33
Molecular cloning and nucleotide sequencing of the gene for E. coli cAMP receptor protein. Nucleic Acids Res (1982) 4.77
Structure of a complex of catabolite gene activator protein and cyclic AMP refined at 2.5 A resolution. J Mol Biol (1987) 4.41
Stringent spacing requirements for transcription activation by CRP. Cell (1990) 3.52
Conformation of beta-hairpins in protein structures. A systematic classification with applications to modelling by homology, electron density fitting and protein engineering. J Mol Biol (1989) 2.86
Helical phase dependent action of CRP: effect of the distance between the CRP site and the -35 region on promoter activity. Nucleic Acids Res (1990) 2.40
Model of specific complex between catabolite gene activator protein and B-DNA suggested by electrostatic complementarity. Proc Natl Acad Sci U S A (1984) 2.32
Deletion mutagenesis of the Escherichia coli galactose operon promoter region. J Mol Biol (1983) 2.09
Scanning calorimetric study of the thermal unfolding of catabolite activator protein from Escherichia coli in the absence and presence of cyclic mononucleotides. Biochemistry (1988) 2.00
Recognition of nucleotide sequences at the Escherichia coli galactose operon P1 promoter by RNA polymerase. Gene (1989) 1.85
Mutants of the catabolite activator protein of Escherichia coli that are specifically deficient in the gene-activation function. Proc Natl Acad Sci U S A (1987) 1.81
Mutations that alter the allosteric nature of cAMP receptor protein of Escherichia coli. EMBO J (1985) 1.80
Upstream activating sequences that are shared by two divergently transcribed operons mediate cAMP-CRP regulation of pilus-adhesin in Escherichia coli. Mol Microbiol (1989) 1.80
Cloning of binding sequences for the Escherichia coli transcription activators, FNR and CRP: location of bases involved in discrimination between FNR and CRP. Nucleic Acids Res (1989) 1.43
Alterations in the binding site of the cyclic AMP receptor protein at the Escherichia coli galactose operon regulatory region. Biochem J (1988) 1.40
Binding of the Escherichia coli cyclic AMP receptor protein to DNA fragments containing consensus nucleotide sequences. Biochem J (1989) 1.35
Comparison of promoter activities in Escherichia coli and Pseudomonas aeruginosa: use of a new broad-host-range promoter-probe plasmid. FEMS Microbiol Lett (1990) 1.31
Regulatory effect of a synthetic CRP recognition sequence placed downstream of a promoter. Nucleic Acids Res (1988) 1.17
Tandem DNA-bound cAMP-CRP complexes are required for transcriptional repression of the deoP2 promoter by the CytR repressor in Escherichia coli. Mol Microbiol (1990) 1.10
Semisynthetic promoters activated by cyclic AMP receptor protein of Escherichia coli. Gene (1989) 1.04
Transection of the oesophagus for bleeding oesophageal varices. Br J Surg (1973) 26.26
A protein interaction map of Drosophila melanogaster. Science (2003) 20.06
An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med (1992) 18.11
Pre-early adenovirus 5 gene product regulates synthesis of early viral messenger RNAs. Cell (1979) 12.83
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet (2013) 9.46
Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell (1982) 9.27
The genome of the social amoeba Dictyostelium discoideum. Nature (2005) 9.18
Cyclic AMP receptor protein: role in transcription activation. Science (1984) 8.37
Mapping temperature-sensitive and host-range mutations of adenovirus type 5 by marker rescue. Virology (1978) 8.28
GPs in principle but not in practice: a study of vocationally trained doctors not currently working as principals. BMJ (1995) 8.09
Early indicators of prognosis in fulminant hepatic failure. Gastroenterology (1989) 7.43
Cost analysis of early discharge after hip fracture. BMJ (1993) 6.64
Deaths from low dose paracetamol poisoning. BMJ (1998) 6.63
Transcriptional regulation by cAMP and its receptor protein. Annu Rev Biochem (1993) 6.49
A quantitative approach to perceived health status: a validation study. J Epidemiol Community Health (1980) 6.29
Anti-tuberculous therapy and acute liver failure. Lancet (1995) 6.27
Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest (1999) 6.13
Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J (1996) 6.08
Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med (2000) 6.07
Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med (2001) 6.05
Prenatal screening for Down's syndrome with use of maternal serum markers. N Engl J Med (1992) 5.21
The Nottingham Health Profile: subjective health status and medical consultations. Soc Sci Med A (1981) 5.02
Acute liver failure: redefining the syndromes. Lancet (1993) 4.99
Vulnerability genes or plasticity genes? Mol Psychiatry (2009) 4.96
Influence of substrate wettability on the attachment of marine bacteria to various surfaces. Appl Microbiol (1975) 4.70
Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result? Lancet (1990) 4.57
Urinary D-glucaric-acid excretion as a test for hepatic enzyme induction in man. Lancet (1971) 4.49
Host-range mutants of adenovirus type 5 defective for growth in HeLa cells. Virology (1977) 4.40
Liver transplantation in man. I. Observations on technique and organization in five cases. Br Med J (1968) 4.38
Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. Lancet (1990) 4.27
HIV-1 reverse transcription. A termination step at the center of the genome. J Mol Biol (1994) 4.15
Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med (1996) 4.10
Daily variation of particulate air pollution and poor cardiac autonomic control in the elderly. Environ Health Perspect (1999) 4.07
Cell-mediated immunity to a human liver-specific antigen in patients with active chronic hepatitis and primary biliary cirrhosis. Lancet (1972) 3.90
Change in use of asthma as a diagnostic label for wheezing illness in schoolchildren. BMJ (1989) 3.80
Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. J Virol (1997) 3.79
The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med (2000) 3.78
The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection. J Virol (1997) 3.77
The influence of dominance rank on the reproductive success of female chimpanzees. Science (1997) 3.74
Synthetic curved DNA sequences can act as transcriptional activators in Escherichia coli. EMBO J (1989) 3.69
Inadequate antibody response to hBAg or suppressor T-cell defect in development of active chronic hepatitis. Lancet (1974) 3.61
Defective transforming capacity of adenovirus type 5 host-range mutants. Virology (1978) 3.52
Stringent spacing requirements for transcription activation by CRP. Cell (1990) 3.52
Physical mapping of temperature-sensitive mutations of adenoviruses. Cold Spring Harb Symp Quant Biol (1975) 3.42
Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess (2007) 3.40
Histone-like protein H1 (H-NS), DNA supercoiling, and gene expression in bacteria. Cell (1990) 3.39
Structured patient education: the diabetes X-PERT Programme makes a difference. Diabet Med (2006) 3.36
Detection of antibodies directed against a liver-specific membrane lipoprotein in patients with acute and chronic active hepatitis. N Engl J Med (1978) 3.28
Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med (1992) 3.24
NHLBI Family Heart Study: objectives and design. Am J Epidemiol (1996) 3.21
Cell-cycle arrest versus cell death in cancer therapy. Nat Med (1997) 3.18
Lymphocyte cytotoxicity to isolated hepatocytes in chronic active hepatitis. Nature (1974) 3.17
Purification and characterization of human liver-specific membrane lipoprotein (LSP). Clin Exp Immunol (1977) 3.13
Generic inhalers for asthma. BMJ (1994) 3.09
A multirater validation study to assess the reliability of acne lesion counting. J Am Acad Dermatol (1996) 3.09
Improved survival after orthotopic liver grafting. Br Med J (Clin Res Ed) (1981) 3.09
Specificity of T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: evidence that T cells are directed against HBV core antigen expressed on hepatocytes. J Immunol (1982) 3.09
Presence of a newly described human DNA virus (TTV) in patients with liver disease. Lancet (1998) 3.06
Liver transplantation for malignant disease. Results in 93 consecutive patients. Ann Surg (1988) 3.04
Discriminating between normal and glaucomatous eyes using the Heidelberg Retina Tomograph, GDx Nerve Fiber Analyzer, and Optical Coherence Tomograph. Arch Ophthalmol (2001) 2.99
Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet (1973) 2.98
Use of partial cardiopulmonary bypass during the anhepatic phase of orthotopic liver grafting. Lancet (1979) 2.98
Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. BMJ (1991) 2.94
More donor organs for transplantation. Elective ventilation proposals. J R Coll Physicians Lond (1993) 2.91
Broad host range plasmids carrying the Escherichia coli lactose and galactose operons. FEMS Microbiol Lett (1992) 2.90
Multisystem involvement in chronic liver disease. Studies on the incidence and pathogenesis. Am J Med (1973) 2.88
Role of alginate and its O acetylation in formation of Pseudomonas aeruginosa microcolonies and biofilms. J Bacteriol (2001) 2.87
Altered calcium metabolism in epileptic children on anticonvulsants. Br Med J (1971) 2.86
Purchasing for all: an alternative to fundholding. BMJ (1994) 2.86
The arthropathy of idiopathic haemochromatosis. Q J Med (1968) 2.85
Hepatitis B virus infection in medical and health care personnel. Br Med J (Clin Res Ed) (1982) 2.85
Liver transplantation after paracetamol overdose. BMJ (1991) 2.81
Multiple control of flagellum biosynthesis in Escherichia coli: role of H-NS protein and the cyclic AMP-catabolite activator protein complex in transcription of the flhDC master operon. J Bacteriol (1999) 2.80
New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol (1997) 2.78
Liver disease and bile duct abnormalities in adults with cystic fibrosis. Lancet (1989) 2.76
Liver in Felty's syndrome. Br Med J (1970) 2.75
Mechanism of CRP-cAMP activation of lac operon transcription initiation activation of the P1 promoter. J Mol Biol (1984) 2.74
Kinetics of open complex formation between Escherichia coli RNA polymerase and the lac UV5 promoter. Evidence for a sequential mechanism involving three steps. Biochemistry (1985) 2.71
Hepatic damage and death from overdose of paracetamol. Lancet (1973) 2.70
'Ending up a GP': a qualitative study of junior doctors' perceptions of general practice as a career. Fam Pract (1997) 2.70
Interaction and dose equivalence of salbutamol and salmeterol in patients with asthma. BMJ (1993) 2.70
Physical mapping of temperature-sensitive mutations of adenoviruses. J Mol Biol (1975) 2.69
Kinetics of the allosteric interactions of phosphofructokinase from Escherichia coli. J Mol Biol (1968) 2.69
Extrahepatic biliary atresia versus neonatal hepatitis. Review of 137 prospectively investigated infants. Arch Dis Child (1976) 2.67
Cyclosporin A in cadaveric organ transplantation. Br Med J (Clin Res Ed) (1981) 2.67
Viral DNA sequences in cells transformed by simian virus 40, adenovirus type 2 and adenovirus type 5. Cold Spring Harb Symp Quant Biol (1975) 2.65
Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med (1991) 2.65
Reverse transcriptases and genomic variability: the accuracy of DNA replication is enzyme specific and sequence dependent. EMBO J (1990) 2.64
Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology (1999) 2.62
Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology (1988) 2.60
Treatment of hepatic encephalopathy. N Engl J Med (1997) 2.60
International differences in understanding recovery: systematic review. Epidemiol Psychiatr Sci (2012) 2.57
Liver transplantation. Curr Probl Surg (1979) 2.57